Cargando…
Cardiotoxicity risk factors with immune checkpoint inhibitors
BACKGROUND: Checkpoint-inhibitor immunotherapies have had a profound effect in the treatment of cancer by inhibiting down-regulation of T-cell response to malignancy. The cardiotoxic potential of these agents was first described in murine models and, more recently, in numerous clinical case reports...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915459/ https://www.ncbi.nlm.nih.gov/pubmed/35277208 http://dx.doi.org/10.1186/s40959-022-00130-5 |